Dr. Wesolowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-6529Fax+1 614-293-9429
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010- Cleveland Clinic FoundationResidency, Internal Medicine, 2004 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
OH State Medical License 2004 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Start of enrollment: 2011 Oct 01
- Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Start of enrollment: 2012 May 01
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Start of enrollment: 2016 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 129 citationsMyeloid-derived suppressor cells in breast cancer.Joseph Markowitz, Robert Wesolowski, Tracey L. Papenfuss, Taylor R. Brooks, William E. Carson
Breast Cancer Research and Treatment. 2013-07-05 - 54 citationsModeling combination therapy for breast cancer with BET and immune checkpoint inhibitorsXiulan Lai, Andrew Stiff, Megan C. Duggan, Robert Wesolowski, William E. Carson
Proceedings of the National Academy of Sciences of the United States of America. 2018-05-22 - 5 citationsAssociation of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.Sarah Asad, Adrienne Damicis, Yujing J Heng, Kathryn Kananen, Katharine A Collier
Breast Cancer Research. 2022-11-14
Journal Articles
- Modeling Combination Therapy for Breast Cancer with BET and Immune Checkpoint InhibitorsRobert Wesolowski, Andrew Stiff, Proceedings of the National Academy of Sciences
Press Mentions
Bexion Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for BXQ-350 in Advanced Solid TumorsOctober 31st, 2024- Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
- Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
